{
 "awd_id": "9160618",
 "agcy_id": "NSF",
 "tran_type": "Grant",
 "awd_istr_txt": "Standard Grant",
 "awd_titl_txt": "Reversed Micellar Fractionation of Recombinant-DNA          Therapeutic Protein Intermediates",
 "cfda_num": "47.084",
 "org_code": "15030000",
 "po_phone": null,
 "po_email": "",
 "po_sign_block_name": "Ritchie B. Coryell",
 "awd_eff_date": "1992-03-15",
 "awd_exp_date": "1992-12-31",
 "tot_intn_awd_amt": 50000.0,
 "awd_amount": 50000.0,
 "awd_min_amd_letter_date": "1992-03-06",
 "awd_max_amd_letter_date": "1992-03-06",
 "awd_abstract_narration": "Bio-Eng is developing a continuous flow reversed                                micellar-organic phase (RM-ORG) process for the initial                         fractionation or purification of recombinant-DNA                                therapeutic protein intermediates which are harvested from                                                                                                      a fermentation broth.  The proposed RM-ORG process will                         not compete with, but will rather complement high                               resolution chromatographic purification steps.  RM-ORG                          fractionation would increase throughput capacity by                             reducing the loading on higher resolution chromatographic                       purification steps, and would thus reduce production time                       and costs.  Modest to high improvements in specificity (2                       to 10 fold) and high yields (95 to 100%) are anticipated.                                                                                                       Other intrinsic benefits to the RM-ORG process such as                          process stream clarification, concentration and buffer                          exchange are also anticipated.  Potential advantages of                         RM-ORG over existing primary purification processes                             include selectivity, speed of processing, preservation of                       protein integrity, and scalability.",
 "awd_arra_amount": 0.0,
 "dir_abbr": "TIP",
 "org_dir_long_name": "Directorate for Technology, Innovation, and Partnerships",
 "div_abbr": "TI",
 "org_div_long_name": "Translational Impacts",
 "awd_agcy_code": "4900",
 "fund_agcy_code": "4900",
 "pi": [
  {
   "pi_role": "Principal Investigator",
   "pi_first_name": "Trevor",
   "pi_last_name": "Castor",
   "pi_mid_init": "P",
   "pi_sufx_name": "",
   "pi_full_name": "Trevor P Castor",
   "pi_email_addr": "aphios@aol.com",
   "nsf_id": "000159019",
   "pi_start_date": "1992-03-15",
   "pi_end_date": null
  }
 ],
 "inst": {
  "inst_name": "Aphios Corporation",
  "inst_street_address": "87 MAIN ST",
  "inst_street_address_2": "",
  "inst_city_name": "NORTH READING",
  "inst_state_code": "MA",
  "inst_state_name": "Massachusetts",
  "inst_phone_num": "6179326933",
  "inst_zip_code": "018642205",
  "inst_country_name": "United States",
  "cong_dist_code": "06",
  "st_cong_dist_code": "MA06",
  "org_lgl_bus_name": "APHIOS CORP",
  "org_prnt_uei_num": "",
  "org_uei_num": "HDE2J1H521A7"
 },
 "perf_inst": {
  "perf_inst_name": "DATA NOT AVAILABLE",
  "perf_str_addr": "",
  "perf_city_name": "",
  "perf_st_code": "",
  "perf_st_name": "RI REQUIRED",
  "perf_zip_code": "",
  "perf_ctry_code": "",
  "perf_cong_dist": "",
  "perf_st_cong_dist": "",
  "perf_ctry_name": "",
  "perf_ctry_flag": "0"
 },
 "pgm_ele": [
  {
   "pgm_ele_code": "537100",
   "pgm_ele_name": "SBIR Phase I"
  }
 ],
 "pgm_ref": [
  {
   "pgm_ref_code": "1402",
   "pgm_ref_txt": "BIOCHEMICAL & BIOMASS ENG"
  },
  {
   "pgm_ref_code": "5371",
   "pgm_ref_txt": "SMALL BUSINESS PHASE I"
  }
 ],
 "app_fund": [
  {
   "app_code": "",
   "app_name": "",
   "app_symb_id": "",
   "fund_code": "",
   "fund_name": "",
   "fund_symb_id": ""
  }
 ],
 "oblg_fy": [
  {
   "fund_oblg_fiscal_yr": 1992,
   "fund_oblg_amt": 50000.0
  }
 ],
 "por": null
}